Wesley M. Jackson (Chief Executive Officer) has been actively involved in biotechnology entrepreneurship for over 12 years. Wesley has been the principal investigator of eight NIH projects at Valitor to optimize the manufacturing, characterization, and formulation of multivalent protein conjugate drugs and to evaluate their performance in relevant disease models. He recently led the fundraising efforts to close Valitor’s successful Series A financing.
Livia W. Brier (Nonclinical Studies Director) joined Valitor in June 2016 to lead preclinical and nonclinical research studies to demonstrate the safety and efficacy of our MVP conjugate products. Previously, she was an HHMI postdoctoral scholar in the laboratory of Prof. Randy Schekman at UC Berkeley.
Amy A. Twite (Director of Chemistry) joined Valitor in August 2018 to lead the optimization, scale-up and manufacturing technology transfer of our MVP conjugate products. She has led similar product positions to manage product development, scale-up and launch at Novozymes, Inc., Adheren Biologics, Inc., and Indee Labs, Inc.
Directors and Key Advisors
Kevin Healy (Co-Founder and Board Member) is a UC Berkeley Professor of Materials Science Engineering and Bioengineering with over 25 years of research developing biomaterials-based biotechnologies. Kevin has pursued the commercialization of these technologies by founding BioEngineered Materials, Inc., Cardiomimetics, Inc., and most recently, mOrganos, Inc.
Drew Lanza (Board Member) is a founding partner of the Berkeley Catalyst Fund and previously spent more than a decade as a general partner at Morgenthaler Ventures. He has been a founder for 5 technology companies and served on the board of directors for more than 10 early-stage companies.
Lewis Lanier (Scientific Advisor) is a Chair of the Department of Microbiology and Immunology at UCSF School of Medicine and the UCSF Director of the Parker Institute for Cancer Immunology. He has extensive research experience in studying the immune system, and he has more than three decades of experience designing mouse experiments to study immune cell function.
Walter Moos (Board Member) is the Founding CEO of ShangPharma Innovations and was previously a Vice President at Chiron (acquired by Novartis) and Warner-Lambert/Parke-Davis (acquired by Pfizer). He has since served as Chairman/CEO of MitoKor (acquired by Migenix) and as a board member for more than 20 organizations, including Axiom Biotechnologies (acquired by Sequenom), Circle Pharma, Mimotopes (acquired by Thermo Fisher), Oncologic (now Aduro), and Onyx (acquired by Amgen).
David Schaffer (Co-Founder and Chair of Scientific Advisory Board) is currently a UC Berkeley Professor of Chemical Engineering and has over 20 years of research with specific expertise in molecular engineering of biologic therapeutics, which has resulted in more than 12 biotechnology patents. He is also a co-founder and director of IGNITE Immunotherapy, Inc. and 4D Molecular Therapeutics, Inc., where he has negotiated six strategic partnerships with major biotech companies and raised more than $10MM in private venture capital investments.
Paul Shields (Chemistry and Manufacturing Advisor) has 24 years of experience in the biopharmaceutical industry with a specific focus on operations, management, and finance. He has contributed to the development of Valitor’s overall business plan, licensing strategy, and fundraising strategy. Paul also assists Valitor’s management team with strategic partnership identification.